Priority Review for Bayer's PI3K in follicular lymphoma

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for copanlisib (BAY 80-6946) as a third-line therapy to treat relapsed or refractory follicular lymphoma. Bayer expects a...